Because serum levels of PTH and FGF23 increase in response to phosphate loading, lowering serum phosphate and reducing phosphate loading is of primary importance for the management of CKD–MBD in hemodialysis patients [16]. This evidence concerns the gene PTH and Marchiafava-Bignami disease.